在不同年龄组的血液恶性瘤患者的基因组差异
Xiaodi Yang1, Qian Wang1, Yuhua Sun1
1Department of Hematology, Peking University First Hospital, Beijing, China.
Communications biology
|December 6, 2024
概括
血液恶性瘤在儿童/年轻人 (CYA) 和老年人 (OA) 之间表现出明显的临床和基因组差异. 了解这些与年龄相关的差异,包括突变和拷贝数的改变,是个性化癌症治疗的关键.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 基因组学就是基因组学.
背景情况:
- 血液性恶性瘤对所有年龄组的健康构成重大负担.
- 血液癌的生物学基础和年龄特异性差异尚未完全理解.
研究的目的:
- 为了比较儿童/年轻成年人 (CYA) 与老年人 (OA) 血液恶性瘤的临床和基因组特征.
- 为了识别基因突变,拷贝数改变和驱动基因融合中的与年龄相关的差异.
- 为特定年龄的个性化治疗策略提供见解.
主要方法:
- 在CYA和OA患者队列之间对临床数据和基因组资料进行比较分析.
- 在不同年龄组中识别差异突变基因 (DMGs) 和拷贝数改变 (CNAs).
- 对已识别的DMG的蛋白质-蛋白质相互作用网络的研究.
主要成果:
- 观察到显著的临床差异,包括性别,种族,转移率和瘤亚型.
- 与OA相比,CYA血液恶性瘤通常具有较低的突变负担.
- 确定了不同的DMG组,其中TP53,TET2和DNMT3A在CYA中变异较少,而NRAS,KRAS和其他在CYA中更常见. CYA恶性瘤显示出更多的拷贝数变化和驱动基因融合.
- 在CYA和OA之间,在ARID1B,MYB,TP53和ESR1之间注意到CNA差异.
结论:
- 血液性恶性瘤表现出与年龄相关的显著临床和基因组差异.
- 在CYA和OA中识别特定的遗传变异为适合年龄的治疗提供了基础.
- 对比基因组分析揭示了开发不同年龄组个性化治疗方法的关键见解.
相关概念视频
01:22Bone Marrow Sampling and Transplants
284
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
284
01:01Regulation of Hematopoietic Stem Cells
3.1K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.1K
01:21Hematopoiesis
5.1K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.1K
01:15Differentiation of Common Myeloid Progenitor Cells
3.2K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.2K
01:20Overview of Hematopoiesis
3.8K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
3.8K